DEA Rules on Doctor's Fate in Routine Order
Published Date: 12/22/2025
Notice
Summary
Dr. David Halvorson from Alabama lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of October 31, 2025. This means he can’t prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Halvorson
The DEA revoked David Halvorson, M.D.'s Certificate of Registration No. BH3453278 and denied any pending applications to renew, modify, or obtain additional registration in Alabama. The Order is effective January 21, 2026; the record also shows his Alabama medical license was revoked on or about June 6, 2025 and his DEA registration expired on October 31, 2025.
DEA Policy: State Authority Required
Under 21 U.S.C. 824(a)(3) and long-standing DEA precedent cited in this Order, the DEA will revoke a practitioner's federal controlled-substances registration if the practitioner no longer has state authority to dispense controlled substances (for example, after a state license suspension or revocation). The Order reiterates that possession of state authority to dispense controlled substances is a fundamental condition for obtaining and maintaining a DEA practitioner registration.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-23544 — Notice of Inventory Completion: Florida Department of State, Tallahassee, FL
The Florida Department of State has finished checking some Native American human remains and found they belong to the Pueblo of Jemez tribe. Starting January 21, 2026, these remains can be returned to the tribe. This is part of a respectful effort to give back important cultural items and remains to Native communities.
Next: 2025-23546 — Submission for Office of Management and Budget Review; Proposed Information Collection Activity; Office of Community Services Community Economic Development Performance Progress Report
The Office of Community Services is updating how community economic development grant recipients report their progress. New awardees will now submit shorter reports every quarter, while others stick to twice a year. This change helps keep projects on track and improves how the government supports and tracks job creation and spending, with comments due by January 21, 2026.